Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Future of the Stem Cell Market

Executive Summary

The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.

You may also be interested in...



Time To Strike On Regenerative Medicine/Stem Cell Companies?

As the hype that accompanied the revelation of regenerative medicine recedes, biotechs that survived the transition from science experiment to market-focused company have now settled into the same realities that face the rest of the industry in terms of making the case for reimbursement and preparing for regulatory scrutiny, not to mention the exit question.

Breast Implant Update: Scrutiny Continues

At an FDA General and Plastic Surgery Devices panel held in August to make recommendations on postmarketing issues related to silicone gel breast implants, the agency said it will continue to monitor patient safety via the postapproval studies and surgeon adverse reports and has asked that groups work together to improve follow-up and registry enrollment.

Breast Implant Update: Scrutiny Continues

At an FDA General and Plastic Surgery Devices panel held in August to make recommendations on postmarketing issues related to silicone gel breast implants, the agency said it will continue to monitor patient safety via the postapproval studies and surgeon adverse reports and has asked that groups work together to improve follow-up and registry enrollment.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel